There is a consensus that the treatment goal for patients with generalized MG (gMG) should be achievement of a Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), defined as having no symptoms indicating functional limitations, or better. 1, –, 3 These patients are considered to have refractory MG, which can severely affect their health-related quality of life and increase the socioeconomic burden of the disease. ![]() In most patients with myasthenia gravis (MG), the disease is managed using immunosuppressive therapies (ISTs) however, 10%–15% of patients do not respond adequately to ISTs, experience intolerable adverse events, or require maintenance IV immunoglobulin or plasma exchange treatment. Glossary AChR+ = anti-acetylcholine receptor-positive CI = confidence interval gMG = generalized myasthenia gravis IST = immunosuppressive therapy MG = myasthenia gravis MG-ADL = Myasthenia Gravis Activities of Daily Living MGFA = Myasthenia Gravis Foundation of America MM = minimal manifestations OR = odds ratio PR = pharmacologic remission REGAIN = Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |